Schou Jakob Vasehus, Johansen Julia Sidenius, Nielsen Dorte, Rossi Simona
Department of Oncology, Herlev & Gentofte Hospital, DK-2730 Herlev, Denmark.
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Nørregade 10, DK-1165 Copenhagen, Denmark.
Noncoding RNA. 2016 Jun 1;2(2):5. doi: 10.3390/ncrna2020005.
MiRNAs are suggested as promising cancer biomarkers. They are stable and extractable from a variety of clinical tissue specimens (fresh frozen or formalin fixed paraffin embedded tissue) and a variety of body fluids (e.g., blood, urine, saliva). However, there are several challenges that need to be solved, considering their potential as biomarkers in cancer, such as lack of consistency between biomarker panels in independent studies due to lack of standardized sample handling and processing, use of inconsistent normalization approaches, and differences in patients populations. Focusing on colorectal cancer (CRC), divergent results regarding circulating miRNAs as prognostic or predictive biomarkers are reported in the literature. In the present review, we summarize the current data on circulating miRNAs as prognostic/predictive biomarkers in patients with localized and metastatic CRC (mCRC).
微小RNA（miRNAs）被认为是很有前景的癌症生物标志物。它们稳定，可从多种临床组织标本（新鲜冷冻或福尔马林固定石蜡包埋组织）以及多种体液（如血液、尿液、唾液）中提取。然而，考虑到它们作为癌症生物标志物的潜力，仍有几个挑战需要解决，例如由于缺乏标准化的样本处理和加工，独立研究中的生物标志物面板之间缺乏一致性，使用不一致的标准化方法，以及患者群体的差异。聚焦于结直肠癌（CRC），文献报道了关于循环miRNAs作为预后或预测生物标志物的不同结果。在本综述中，我们总结了目前关于循环miRNAs作为局限性和转移性结直肠癌（mCRC）患者预后/预测生物标志物的现有数据。
